Inovio Pharmaceuticals doses first subject in Zika vaccine clinical trial
Inovio Pharmaceuticals announced the dosing of the first subject in its multi-center phase I trial to evaluate Inovio’s Zika DNA vaccine (GLS-5700). In addition, Health Canada’s Health Products and Food Branch has also approved this study. July 26, 2016